- Home
- EDD vs PROK Comparison
EDD vs PROK Comparison
Compare EDD & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDD | PROK |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.5M | 331.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EDD | PROK |
|---|---|---|
| Price | $5.69 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 254.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $956.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.22 | $0.46 |
| 52 Week High | $4.95 | $7.13 |
Technical Indicators
Market Signals| Indicator | EDD | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 62.99 | 49.22 |
| Support Level | $5.54 | $2.15 |
| Resistance Level | $5.74 | $2.37 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 86.36 | 45.96 |
Price Performance
Historical ComparisonAbout EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.